FDA Blocks Viatris US Products With India Facility Import Alert
Viatris: Necessary Corrective And Preventive Actions Are Well Underway
Viatris has told investors it will incorporate any potential future financial impact into its soon-to-be-released 2025 guidance ranges, after the firm’s oral finished dose manufacturing facility in Indore, India, was slapped with a US Food and Drug Administration import alert and warning letter.
